Business Wire

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

10.5.2023 10:32:00 EEST | Business Wire | Press release

Share

Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint. These results including an analysis of the actual maintenance dose indicating even greater weight loss will be presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S. Until then, the data is under embargo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005447/en/

“Obesity is one of many cardio-renal-metabolic diseases, which together represent one of the fastest growing health challenges worldwide. The distinct mode of action of BI 456906 targets multiple pathways pivotal to metabolic regulation, including those associated with obesity and liver diseases,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “With our longstanding heritage in cardio-renal-metabolic diseases, we are excited by the findings and potential implications for millions of people who urgently need healthcare solutions.”

“We are both enthusiastic about these data and encouraged by the clinical outcomes announced today,” said David Kendall, M.D., Chief Medical Officer, Zealand Pharma. “At Zealand Pharma we continue our long-term commitment to the discovery and development of novel differentiated peptide therapeutics that target critical metabolic pathways to achieve substantial weight loss while addressing the complex pathophysiology of overweight and obesity.”

In 2016, more than 1 billion people worldwide were living with cardio-renal-metabolic (CRM) diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure and cardiovascular disease1-10. Obesity is a major global health challenge, and the worldwide prevalence has more than doubled over the past four decades11. The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with obesity or overweight, placing a high burden on individuals, healthcare systems and society11.

Notes to editors

Please click on the following link for ‘Notes to editors’ and ‘References’

https://www.boehringer-ingelheim.com/phase-ll-trial-results-in-obesity-or-overweight

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Harro ten Wolde
Global Head of Media Relations
Boehringer Ingelheim
Email: harro.ten_wolde@boehringer-ingelheim.com

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 14:05:00 EET | Press release

At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119101038/en/ Ant International at the Singapore Fintech Festival 2026 YP highlighted three critical angles to tackle the future financial system: How should settlement infrastructure evolve in the AI + blockchain era to establish new game rules? How to build cross-rail, cross-modal trust for the agentic economy? How to mainstream inclusion into AI design to close the accessibility gap for SMEs? The Missing Debate: Rewiring settlement infrastructure The four-party payment model — issuer, acquirer, network, regulator — has served as a mature bedrock for traditional economy. However, would we still need the acqu

NIQ Appoints Danny Lange and Chris Tung to Board of Directors19.11.2026 13:45:00 EET | Press release

NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that Danny Lange and Chris Tung have been appointed to its Board of Directors, effective Nov. 18, 2026. Lange brings more than three decades of technology leadership, including senior roles building and scaling artificial intelligence and machine learning capabilities at Google, Unity, Uber, Amazon and Microsoft. Tung brings extensive operating, consumer and digital commerce experience across Greater China and Asia Pacific through leadership roles at Shangri-La Asia, Alibaba, PepsiCo, L’Oréal and other global businesses. Together, their experience strengthens the Board’s perspective as NIQ advances its AI strategy and expands its impact across global markets. “Danny and Chris bring expertise that directly aligns with where NIQ is going,” said Jim Peck, Executive Chairman and Chief Executive Officer of NIQ. “Danny has spent his career building AI and machine learning capabilities at scale. Chris brings deep

Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 119.11.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation f

SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 13:00:00 EET | Press release

Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Business and Technology Services, and we see multiple ways to add value alongside the team as SRM’s first institutional investor. We’re excited to partner with Brad D

Pretium Expands Real Estate Debt Platform19.11.2026 13:00:00 EET | Press release

Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a housing shortage of approximately four to five million homes, and the Hilltop team has built an impress

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye